Back

Short term effect of SGLT2 inhibitor, Dapagliflozin added on to standard therapy in decompensated heart failure patients with diabetes mellitus

29 August 2017 (10:05 - 10:55)
Organised by:
Congress Presentation Part of: Fresh look at heart failure AHF - Drug treatment ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Masaki Nakagaito

University of Toyama, Toyama (Japan)

6 More presentations in this session

Presentation thumbnail
Do beta-blockers improve one-year survival in heart failure patients with atrial fibrillation? Results from the ESC-HF Registry
Doctor K. Ozieranski (Warsaw, PL)
Abstract Slides
Presentation thumbnail
Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation in the PREFER in AF registry
Associate Professor J. Siller-Matula (Vienna, AT)
Abstract Slides
Presentation thumbnail
Association between serum potassium and clinical outcomes in UK patients with heart failure
Ms L. Qin (Gaithersburg, US)
Abstract Slides
Presentation thumbnail
Presence of micro- and macroalbuminuria and association with cardiac mechanics in type 2 diabetes
Doctor P. Jorgensen (Hellerup, DK)
Abstract Slides
Presentation thumbnail
Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c
Doctor D. Fitchett (Toronto, CA)
Abstract Slides

Access the full session

Session thumbnail
Fresh look at heart failure

The Event

Event poster

ESC Congress 2017

29 August 2017 10:05 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources